Zhang Zhengwei, financial director of Northeast Pharmaceutical, stressed in the dingzeng roadshow that the company is now gradually completing the transformation from API to pharmaceutical industry chain, and the biopharmaceutical sector will also become a new performance growth point of the company
"This year, it is expected that five biopharmaceuticals will be approved, and in the next three years, five to six hepatitis B and hepatitis C drugs will be approved."
Wei Haijun, chairman of Northeast Pharmaceutical, also disclosed to investors that a new anti infective drug developed by the US Pharmaceutical Research Institute has completed in vitro test in Japan, "it is expected to be applied for clinical application in China within 4-5 years"
After use, it will not produce drug resistance, which is subversive for the whole anti infective drug
According to the State Food and drug administration, the only viable Bacillus licheniformis granules and capsules belonging to biological products of Northeast Pharmaceutical are in the "in review" stage, while the chemical eferene tablets and diclofenac sodium and lidocaine hydrochloride injection have just been applied for production, which is difficult to be approved within the year.